Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,111 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neurobehavioral Manifestation Clear all
Recruiting Phase 3 Interventional

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

NCT06937229
View directory record Official record
Conditions
Alzheimer Disease, Agitation
Interventions
KarXT, KarX-EC
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
55 Years to 90 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Parent Supported Weight Reduction in Down Syndrome

NCT01256112
View directory record Official record
Conditions
Down Syndrome
Interventions
Parent Supported Behavioral Intervention, Nutrition/Activity Education (NAE)
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years to 26 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Analysis of Brain Activity to Uncover Brain-behavior Relationships Related to Therapy Outcomes in Aphasia

NCT03550092
View directory record Official record
Conditions
Aphasia
Interventions
Abstract Semantic Association Network Training (AbSANT)
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal

NCT00723177
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
AV411, Placebo (PCB)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Bilateral Repetitive Transcranial Magnetic Stimulation for Auditory Hallucinations Original Study

NCT00567281
View directory record Official record
Conditions
Schizophrenia
Interventions
Magstim Rapid-2 system triggering Magstim Super Rapid system
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Phase 2 Interventional

A Study With RO4917523 in Patients With Fragile X Syndrome

NCT01015430
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Placebo (for RO4917523 ascending doses), Placebo (for RO4917523 fixed dose), RO4917523
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Sacramento, California • Decatur, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 14, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional

Talk With Me Baby: Leveraging Well-Child Care to Enhance the Early Home Language Environment

NCT07132411
View directory record Official record
Conditions
Child Language, Language Delay, Developmental Milestones
Interventions
Patients in Talk With Me Baby Clinics, Patients in Care-As-Usual Clinics
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
1 Day to 2 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Atlanta, Georgia • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

NCT04257929
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Pitolisant oral tablets, Placebo oral tablet
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
13
States / cities
San Diego, California • San Ramon, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Recruiting No phase listed Observational

Pain and Disability Outcomes in Post Amputation Patients

NCT05716321
View directory record Official record
Conditions
Limb Pain, Phantom, Residual Limbs Pain, Disability Physical
Interventions
Not listed
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Active, not recruiting Phase 1 Interventional

Psilocybin-assisted Therapy for Phantom Limb Pain

NCT05224336
View directory record Official record
Conditions
Phantom Limb Pain
Interventions
Psilocybin, Placebo Niacin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Not applicable Interventional Results available

Pulsed Electromagnetic Fields for Post-Amputation Pain

NCT05392803
View directory record Official record
Conditions
Phantom Limb Pain, Residual Limb Pain
Interventions
Active then Sham Treatment, Sham then Active Treatment
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 9:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

Prospective IR-led Sedation Feasibility

NCT07443254
View directory record Official record
Conditions
Anesthesia, Sedation and Analgesia, Interventional Radiology
Interventions
ketamine, Fentanyl (IV), Midazolam
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Phase 4 Interventional

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

NCT05657860
View directory record Official record
Conditions
Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Interventions
Guanfacine Extended Release, Placebo
Drug · Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
6 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 14, 2026, 9:51 AM EDT
Active, not recruiting Not applicable Interventional

Feasibility of the Comfort Measures Only Time Out (CMOT)

NCT05861323
View directory record Official record
Conditions
End of Life, Respiratory Failure, Ventilatory Failure, Coma, Aging
Interventions
Comfort Measures Only Time out (CMOT)
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional

Stimulating the Aging Brain Using Brain and Sensory Stimulation

NCT07650188
View directory record Official record
Conditions
Primary Progressive Aphasia
Interventions
tACS or multisensory stimulation
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Terminated Not applicable Interventional

Speech and Language Therapy After Stroke

NCT00713050
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Imitate Therapy
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Firsthand ID for Pain Control

NCT01823874
View directory record Official record
Conditions
Virtual Reality Pain Distraction
Interventions
virtual reality distraction
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 14, 2026, 9:51 AM EDT
Recruiting No phase listed Observational

Genome Medical Sequencing for Gene Discovery

NCT01087320
View directory record Official record
Conditions
Intellectual Disabilities, Congenital Anomaly, Rare Disorders
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
4 Weeks to 99 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Aerobic Exercise and Aphasia Treatment

NCT02999360
View directory record Official record
Conditions
Aphasia
Interventions
Language therapy, Background Music, Aerobic Exercise
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 14, 2026, 9:51 AM EDT
Recruiting No phase listed Observational

Characterization of Dysmorphology in Subjects With Creatine Transporter Deficiency

NCT05600946
View directory record Official record
Conditions
Cognitive Disorder, Metabolic Disease, Autism Spectrum Disorder
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 40 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Not listed Not applicable Interventional

Efficacy of Nerve Blockade Performed Prior to Surgical Intervention Versus Following Surgical Intervention

NCT02666118
View directory record Official record
Conditions
Pain, Shoulder Injury
Interventions
Preemptive Interscalene Block - Single Shot, Postoperative Interscalene Block- Single Shot, Preemptive Interscalene Block - Catheter, Postoperative Interscalene Block - Catheter
Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 21 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Not applicable Interventional

Up, Down, and All Around: Evaluating Mobility Devices for Young Children With Developmental Disabilities and Delays

NCT06591559
View directory record Official record
Conditions
Down Syndrome, Gross Motor Delay, Cerebral Palsy
Interventions
Permobil Explorer Mini, Portable Mobility Aid for Children (PUMA)
Device
Lead sponsor
University of Washington
Other
Eligibility
12 Months to 60 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 14, 2026, 9:51 AM EDT
Recruiting Not applicable Interventional

HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)

NCT06930846
View directory record Official record
Conditions
Brain Cancer, Brain Tumor, Brain Neoplasms, Primary Brain Tumor, Low-grade Glioma, Oligodendroglioma, Meningioma, Low Grade Astrocytoma, Cognitive Dysfunction, Memory Impairment, Memory Disorders, Memory Dysfunction
Interventions
HOBSCOTCH-CA
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 14, 2026, 9:51 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

NCT01584440
View directory record Official record
Conditions
Agitation, Alzheimer's Disease
Interventions
AVP-923-20, Placebo, AVP-923-30
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fresno, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2021 · Synced Oct 14, 2026, 9:51 AM EDT